Diagnoses DiseaseNCT04743843
Concordance Between Omnyx System With Omnyx .RTS Images and the Omnyx Dynamyx Software With Hamamatsu .NDPI Images
An observational study of Diagnoses Disease, run by Inspirata Europe Ltd. at 1 site in United Kingdom.
Trial summary
This study serves as a validation study for the Omnyx Dynamyx software and Hamamatsu .ndpi image file format, evaluating agreement of diagnosis between whole slide images (WSI) of the Omnyx system (Omnyx scanned .rts images and Omnyx Dynamyx software) and the Omnyx Dynamyx software with the Hamamatsu .ndpi images. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Diagnoses Disease
- What is being tested?
- Omnyx Dynamyx Software
- Type of treatment
- Medical device
- How many people
- 60 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 22 Jan 2019to 15 Nov 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: • H\&Es, IHCs and Special stains available at the time of the original diagnosis
Who may be able to join
- • Approximately 60 surgical pathology cases (20 from each sub-specialty group):
- Dermatopathology;
- Breast;
- Head and Neck • Slides that are no more than 2 years old
Who cannot join
- • Frozen sections; and
- Cytology cases
- Slides that require special non-brightfield optical considerations such as polarization or fluorescence
- Hematology slides
- Slides that require 60x or higher magnification (oil immersion)
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Northern Lincolnshire and Goole NHS Foundation Trust
Lincoln, LN2 5QY
About this study
This study serves as a validation study for the Omnyx Dynamyx software and Hamamatsu .ndpi image file format, evaluating agreement of diagnosis between whole slide images (WSI) of the Omnyx system (Omnyx scanned .rts images and Omnyx Dynamyx software) and the Omnyx Dynamyx software with the Hamamatsu .ndpi images. The primary goal of this study is to demonstrate concordance between the two systems to validate the Omnyx Dynamyx software with the non-Omnyx .ndpi image file type.
Read the detailed description
The overall study design was to compare the diagnosis obtained by .rts WSI from the Omnyx system (Omnyx scanner and Omnyx Software) and diagnosis obtained by .ndpi WSI of the Hamamatsu S360 or similar scanner with the Omnyx Software. Pathologists read cases in the Omnyx Dynamyx software with .rts images from an Omnyx scanner and complete a Preliminary Surgical Pathology Consultant Report that includes a preliminary diagnosis. After a two-week washout period, the pathologists read the same cases in the Omnyx Dynamyx software with .ndpi images from a Hamamatsu scanner. The diagnosis from the Omnyx scanners are provided in the Final Surgical Pathology Consultant Report. Pathologists then complete an Inspirata Whole Slide Imaging Case Worksheet to determine confirmation of diagnosis - that is, agreement/concordance between the WSI from the two scanners.
The study is designed to prove that the diagnosis of a case will be the same when using the Omnyx .rts file type as the Hamamatsu .ndpi file type regardless of tissue or procedure type.
All discrepancies between the two "systems" will be documented and reconciled. Discrepancies categorized as Major or Minor. The Principal Investigator Discordance Review Form will be utilized to document the Principal Investigator's review of those cases where discrepancies were attributed to technical/technological aspects of WSI, such as sub-optimal image quality.
This is a deidentified, retrospective study to evaluate surgical pathology cases, excluding frozen sections and cytology. Formalin-fixed paraffin embedded tissue from sixty (60) cases across a range of three (3) subspecialist categories will be used.
Materials for each case include the original pathology report and the complete set of physical slides from each case at the time of diagnosis. Cases will be no more than two (2) years older than the Date of Protocol.
The pathology reports will be deidentified and the key to match the pathology reports with the deidentified physical slides and deidentified Whole Slide Images (WSI) will be retained and managed by the Study Sponsor.
Each slide will be scanned on the Omnyx VL120 scanner and Hamamatsu S360 scanner with 40x magnification settings and standard compression ratings for each system. Whole slide image data sets will be prepared by deidentified case number (for example, Case1- Case 60) and distributed to at least three (3) pathologists with any pertinent information about the case form the original pathology report EXCEPT the final diagnosis.
Each of the approximately 60 cases will be read in both the Omnyx system with Omnyx .rts images and the Omnyx Dynamyx software with Hamamatsu .ndpi images with a two (2) week wash-out period between the .rts and .ndpi case reads. Each case will only be read once (by the same pathologist) in each of the two modalities. Therefore, if three (3) pathologists participate, each pathologist will be responsible for reading twenty (20) cases in both image formats.
A pathologist will review all Omnyx .rts images first and record the preliminary diagnosis. The pathologist will then read the cases from the Hamamatsu .ndpi images in the Omnyx Dynamyx software and determine concordance between WSI produced by the Omnyx VL 120 scanner and viewed in the Omnyx Dynamyx software and images produced by the Hamamatsu S360 scanner and viewed in the Omnyx Dynamyx software. If the pathologist determines discordance, the PI will complete review of all discordant cases.
Concordance will be reported by subspecialty and overall and will be reported between the original pathology report and the .rts images and the .rts images and the .ndpi images. Discordance must be significant as discerned by the adjudication pathologist. Minor discordance will be measured but only significant discordance will be reported as a primary endpoint of this study.
- Conditions
- Diagnoses Disease
- Being tested
- Omnyx Dynamyx Software
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Omnyx Dynamyx SoftwareDevice
Digital pathology image management and viewing software.
What is being measured
The primary outcome is the main question the study is designed to answer.
Concordance between digitized .rts images and digitized .ndpi images
The proportion of diagnosis between Omnyx .rts images and Hamamatsu .ndpi images using Blyth-Still-Casella 95% confidence interval showed concordant diagnosis for each subspecialty and across all recommended subspecialties.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Feb 2021
- Study start22 Jan 2019
- Primary completion15 Nov 2019
- Study completion15 Nov 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diagnoses DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Inspirata Europe Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Mark Lloyd, Ph.D., Principal investigator, Inspirata, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04743843
- Sponsor's protocol ID
- CD-0042
- Status last verified
- Feb 2021
- First submitted
- 3 Feb 2021
- Last updated
- 8 Feb 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Concordance Between Omnyx System With Omnyx .RTS Images and the Omnyx Dynamyx Software With Hamamatsu .NDPI Images
- ClinicalTrials.gov ID
- NCT04743843
- Acronym / sponsor ID
- CD-0042
- Conditions
- Diagnoses Disease
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Inspirata Europe Ltd.Industry (pharma, biotech, devices)
- Study start
- 22 Jan 2019 (actual)
- Primary completion
- 15 Nov 2019 (actual)
- Study completion
- 15 Nov 2019 (actual)
- First posted
- 8 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study serves as a validation study for the Omnyx Dynamyx software and Hamamatsu .ndpi image file format, evaluating agreement of diagnosis between whole slide images (WSI) of the Omnyx system (Omnyx scanned .rts images and Omnyx Dynamyx software) and the Omnyx Dynamyx software with the Hamamatsu .ndpi images. The primary goal of this study is to demonstrate concordance between the two systems to validate the Omnyx Dynamyx software with the non-Omnyx .ndpi image file type.
Detailed description
The overall study design was to compare the diagnosis obtained by .rts WSI from the Omnyx system (Omnyx scanner and Omnyx Software) and diagnosis obtained by .ndpi WSI of the Hamamatsu S360 or similar scanner with the Omnyx Software. Pathologists read cases in the Omnyx Dynamyx software with .rts images from an Omnyx scanner and complete a Preliminary Surgical Pathology Consultant Report that includes a preliminary diagnosis. After a two-week washout period, the pathologists read the same cases in the Omnyx Dynamyx software with .ndpi images from a Hamamatsu scanner. The diagnosis from the Omnyx scanners are provided in the Final Surgical Pathology Consultant Report. Pathologists then complete an Inspirata Whole Slide Imaging Case Worksheet to determine confirmation of diagnosis - that is, agreement/concordance between the WSI from the two scanners.
The study is designed to prove that the diagnosis of a case will be the same when using the Omnyx .rts file type as the Hamamatsu .ndpi file type regardless of tissue or procedure type.
All discrepancies between the two "systems" will be documented and reconciled. Discrepancies categorized as Major or Minor. The Principal Investigator Discordance Review Form will be utilized to document the Principal Investigator's review of those cases where discrepancies were attributed to technical/technological aspects of WSI, such as sub-optimal image quality.
This is a deidentified, retrospective study to evaluate surgical pathology cases, excluding frozen sections and cytology. Formalin-fixed paraffin embedded tissue from sixty (60) cases across a range of three (3) subspecialist categories will be used.
Materials for each case include the original pathology report and the complete set of physical slides from each case at the time of diagnosis. Cases will be no more than two (2) years older than the Date of Protocol.
The pathology reports will be deidentified and the key to match the pathology reports with the deidentified physical slides and deidentified Whole Slide Images (WSI) will be retained and managed by the Study Sponsor.
Each slide will be scanned on the Omnyx VL120 scanner and Hamamatsu S360 scanner with 40x magnification settings and standard compression ratings for each system. Whole slide image data sets will be prepared by deidentified case number (for example, Case1- Case 60) and distributed to at least three (3) pathologists with any pertinent information about the case form the original pathology report EXCEPT the final diagnosis.
Each of the approximately 60 cases will be read in both the Omnyx system with Omnyx .rts images and the Omnyx Dynamyx software with Hamamatsu .ndpi images with a two (2) week wash-out period between the .rts and .ndpi case reads. Each case will only be read once (by the same pathologist) in each of the two modalities. Therefore, if three (3) pathologists participate, each pathologist will be responsible for reading twenty (20) cases in both image formats.
A pathologist will review all Omnyx .rts images first and record the preliminary diagnosis. The pathologist will then read the cases from the Hamamatsu .ndpi images in the Omnyx Dynamyx software and determine concordance between WSI produced by the Omnyx VL 120 scanner and viewed in the Omnyx Dynamyx software and images produced by the Hamamatsu S360 scanner and viewed in the Omnyx Dynamyx software. If the pathologist determines discordance, the PI will complete review of all discordant cases.
Concordance will be reported by subspecialty and overall and will be reported between the original pathology report and the .rts images and the .rts images and the .ndpi images. Discordance must be significant as discerned by the adjudication pathologist. Minor discordance will be measured but only significant discordance will be reported as a primary endpoint of this study.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- • H\&Es, IHCs and Special stains available at the time of the original diagnosis
Key inclusion criteria (4 listed)
- • Approximately 60 surgical pathology cases (20 from each sub-specialty group):
Key exclusion criteria (5 listed)
- • Frozen sections; and
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Omnyx Dynamyx SoftwareDigital pathology image management and viewing software. | Device | – |
Primary outcome
Concordance between digitized .rts images and digitized .ndpi images
Time frame: 3 months
The proportion of diagnosis between Omnyx .rts images and Hamamatsu .ndpi images using Blyth-Still-Casella 95% confidence interval showed concordant diagnosis for each subspecialty and across all recommended subspecialties.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Feb 2021.
- Individual participant dataSharing planned: No
Related trials for Diagnoses Disease
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Active, not recruitingPhase 1/2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
RecruitingPhase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-hodgkin Lymphoma
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mark Lloyd, Ph.D. principal investigator
Inspirata, Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diagnoses Disease, run by Inspirata Europe Ltd. at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Concordance between digitized .rts images and digitized .ndpi images (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2021.